Cellular targets in diabetic retinopathy therapy

María Lucía Rodríguez1, Iván Millán2, Ángel Luis Ortega3

  • 1Department of Physiology, Faculty of Pharmacy, University of Valencia, Burjassot 46100, Valencia, Spain.

World Journal of Diabetes
|October 11, 2021
PubMed

Insights

Diabetic retinopathy, a complication of diabetes, involves oxidative stress and inflammation. Targeting redox and inflammatory pathways may prevent vision loss by addressing early disease development.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Molecular Medicine

Background:

  • Diabetic retinopathy (DR) is a major complication of diabetes mellitus, often leading to vision loss.
  • Inadequate glycemic control exacerbates DR, driven by oxidative stress and chronic inflammation.
  • Hyperglycemia-induced redox imbalance damages retinal neurons and vasculature.

Purpose of the Study:

  • To review current understanding of diabetic retinopathy pathogenesis.
  • To highlight the limitations of existing treatments for diabetic retinopathy.
  • To propose novel therapeutic targets for early intervention in diabetic retinopathy.

Main Methods:

  • Literature review focusing on the roles of oxidative stress and inflammation in diabetic retinopathy.
  • Analysis of current therapeutic strategies and their efficacy in advanced disease stages.
  • Identification of potential molecular targets for preventative therapies.

Main Results:

  • Oxidative stress and chronic inflammation are key drivers of diabetic retinopathy.
  • Current therapies are often insufficient, acting only in advanced stages and unable to reverse damage.
  • Early intervention strategies targeting redox and inflammatory pathways show promise.

Conclusions:

  • Modulating redox and inflammatory status presents a promising avenue for preventing diabetic retinopathy.
  • Targeting these pathways may halt disease progression and prevent vision loss.
  • Further research into early-stage therapeutic interventions is urgently needed.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
566
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.1K